A Phase 2 Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children’s Oncology Group Phase 1 and Pilot Consortium (ADVL0921)

BACKGROUND: Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor activity was observed in neuroblastoma, acute lymp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Mossé, Yael P., Fox, Elizabeth, Teachey, David T., Reid, Joel M., Safgren, Stephanie L., Carol, Hernan, Lock, Richard B, Houghton, Peter J, Smith, Malcolm A, Hall, David, Barkauskas, Donald A, Krailo, Mark, Voss, Stephan D., Berg, Stacey L., Blaney, Susan M., Weigel, Brenda J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6897379/
https://ncbi.nlm.nih.gov/pubmed/30777875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2675
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados